{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:39Z","timestamp":1791920139247,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There is no consensus concerning restarting anti-tumour necrosis factor (TNF)-\u03b1 therapy for uveitis after treatment for active tuberculosis (TB). We report a case of Behcet disease (BD) in which treatment with TNF inhibitor was successfully resumed after treatment for miliary TB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case report<\/jats:title>\n                <jats:p>A 48-year-old Japanese male was treated for uveitis of unknown aetiology in the left eye at a general ophthalmology clinic. He was referred to Department of Ophthalmology, Tokyo Medical University Hospital because of macula oedema (ME) not responding to prednisolone (PSL) 20\u00a0mg. BD was diagnosed based on fluorescein angiographic findings of diffuse retinal vasculitis characteristic of BD, recurrent oral aphthous ulcer, erythema nodosum-like rash in his legs, and HLA-A26 positivity. After a screening test, adalimumab (ADA) was started as steroid-sparing therapy. Eight months after starting ADA, the patient was diagnosed with miliary TB. ADA and PSL were discontinued immediately due to TB. Anti-TB treatment was completed after 6\u00a0months based on clinical improvement, although T-SPOT.TB was still positive. Infliximab with isoniazid was started due to relapse of ME, worsened vitreous haze, and worsened visual acuity in his left eye. Subsequently, his ocular symptoms subsided and there was no relapse of TB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case suggests that in patients with BD who have discontinued anti-TNF therapy due to miliary TB, restarting anti-TNF therapy may be a therapeutic option after TB has been treated appropriately with careful monitoring for relapse.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12348-023-00375-w","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T20:01:39Z","timestamp":1701201699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resuming anti-TNF therapy after development of miliary tuberculosis in Behcet\u2019s disease-related uveitis: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Chika","family":"Toriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-3745","authenticated-orcid":false,"given":"Kinya","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"issue":"5","key":"375_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/09273948.2019.1709649","volume":"29","author":"K Kunimi","year":"2021","unstructured":"Kunimi K, Usui Y, Tsubota K et al (2021) Changes in etiology of uveitis in a single center in Japan. Ocul Immunol Inflamm 29(5):976\u2013981. https:\/\/doi.org\/10.1080\/09273948.2019.1709649","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"375_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"Okada AA, Goto H, Ohno S, Mochizuki M Ocular Beh\u00e7et's Disease Research Group Of Japan","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M Ocular Beh\u00e7et\u2019s Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol 130(5):592\u2013598. https:\/\/doi.org\/10.1001\/archophthalmol.2011.2698","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"375_CR3","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S et al (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study. Ophthalmology 121(10):1877\u20131884. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.042","journal-title":"Ophthalmology"},{"issue":"10","key":"375_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa1509852","journal-title":"N Engl J Med"},{"key":"375_CR5","doi-asserted-by":"publisher","unstructured":"Sener H, Evereklioglu C, Horozoglu F, Gunay Sener AB (2023). Efficacy and safety of adalimumab in patients with Beh\u00e7et Uveitis: a systematic review and meta-analysis. Ocul Immunol Inflamm. 1\u20139. Advance online publication. https:\/\/doi.org\/10.1080\/09273948.2022.2157288","DOI":"10.1080\/09273948.2022.2157288"},{"issue":"1","key":"375_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","volume":"30","author":"K Kunimi","year":"2022","unstructured":"Kunimi K, Usui Y, Asakage M et al (2022) Anti-TNF-\u03b1 therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm 30(1):223\u2013230. https:\/\/doi.org\/10.1080\/09273948.2020.1791346","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"375_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/25785826.2019.1678961","volume":"24","author":"K Maruyama","year":"2019","unstructured":"Maruyama K (2019) Current standardized therapeutic approach for uveitis in Japan. Immunol Med 24(3):124\u2013134. https:\/\/doi.org\/10.1080\/25785826.2019.1678961","journal-title":"Immunol Med"},{"issue":"6","key":"375_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E et al (2021) Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 128(6):899\u2013909. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.036","journal-title":"Ophthalmology"},{"issue":"3","key":"375_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40123-022-00493-z","volume":"11","author":"K Namba","year":"2022","unstructured":"Namba K, Kaburaki T, Tsuruga H et al (2022) Long-term safety and effectiveness of adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients. Ophthalmol Ther 11(3):1147\u20131161. https:\/\/doi.org\/10.1007\/s40123-022-00493-z","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"375_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","volume":"27","author":"VS Theis","year":"2008","unstructured":"Theis VS, Rhodes JM (2008) Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27(1):19\u201330. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03553.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"375_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/rheumatology\/keu041","volume":"53","author":"YJ Kim","year":"2014","unstructured":"Kim YJ, Kim YG, Shim TS et al (2014) Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford) 53(8):1477\u20131481. https:\/\/doi.org\/10.1093\/rheumatology\/keu041","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"375_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/MIB.0000000000000002","volume":"20","author":"JM Swoger","year":"2014","unstructured":"Swoger JM, Regueiro M (2014) Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis 20(5):926\u2013935. https:\/\/doi.org\/10.1097\/MIB.0000000000000002","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"375_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00296-016-3575-3","volume":"36","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Hatemi G, Ugurlu S et al (2016) Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int 36(12):1719\u20131725. https:\/\/doi.org\/10.1007\/s00296-016-3575-3","journal-title":"Rheumatol Int"},{"key":"375_CR14","doi-asserted-by":"publisher","unstructured":"Evangelatos G, Koulouri V, Iliopoulos A et al (2020) Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 12:1759720X20930116. https:\/\/doi.org\/10.1177\/1759720X20930116","DOI":"10.1177\/1759720X20930116"},{"issue":"12","key":"375_CR15","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.4049\/jimmunol.166.12.7033","volume":"166","author":"E Giacomini","year":"2001","unstructured":"Giacomini E, Iona E, Ferroni L et al (2001) Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 166(12):7033\u20137041. https:\/\/doi.org\/10.4049\/jimmunol.166.12.7033","journal-title":"J Immunol"},{"issue":"6","key":"375_CR16","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","volume":"162","author":"AG Bean","year":"1999","unstructured":"Bean AG, Roach DR, Briscoe H et al (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162(6):3504\u20133511","journal-title":"J Immunol"},{"issue":"11","key":"375_CR17","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1086\/517519","volume":"195","author":"HL Plessner","year":"2007","unstructured":"Plessner HL, Lin PL, Kohno T et al (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195(11):1643\u20131650","journal-title":"J Infect Dis"},{"issue":"4","key":"375_CR18","doi-asserted-by":"publisher","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"H Hamdi","year":"2006","unstructured":"Hamdi H, Mariette X, Godot V et al (2006) Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8(4):R114. https:\/\/doi.org\/10.1186\/ar1994","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"375_CR19","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884\u20131894. https:\/\/doi.org\/10.1002\/art.24632","journal-title":"Arthritis Rheum"},{"key":"375_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D (2014) Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 91:47\u201355. https:\/\/doi.org\/10.3899\/jrheum.140102","journal-title":"J Rheumatol Suppl"},{"issue":"4","key":"375_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1086\/505430","volume":"194","author":"OY Saliu","year":"2006","unstructured":"Saliu OY, Sofer C, Stein DS et al (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194(4):486\u2013492. https:\/\/doi.org\/10.1086\/505430","journal-title":"J Infect Dis"},{"issue":"6","key":"375_CR22","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/art.23460","volume":"58","author":"J Wang","year":"2008","unstructured":"Wang J, van Dongen H, Scherer HU et al (2008) Suppressor activity among CD4+, CD25++ T cells is discriminated by membrane-bound tumor necrosis factor alpha. Arthritis Rheum 58(6):1609\u20131618. https:\/\/doi.org\/10.1002\/art.23460","journal-title":"Arthritis Rheum"},{"issue":"9","key":"375_CR23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","volume":"27","author":"I Hanta","year":"2008","unstructured":"Hanta I, Ozbek S, Kuleci S et al (2008) The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 27(9):1083\u20131086. https:\/\/doi.org\/10.1007\/s10067-008-0867-3","journal-title":"Clin Rheumatol"},{"issue":"10","key":"375_CR24","doi-asserted-by":"publisher","first-page":"e0141033","DOI":"10.1371\/journal.pone.0141033","volume":"10","author":"YJ Jung","year":"2015","unstructured":"Jung YJ, Woo HI, Jeon K et al (2015) The significance of sensitive interferon gamma release assays for diagnosis of latent tuberculosis infection in patients receiving tumor necrosis factor-\u03b1 antagonist therapy. PLoS ONE 10(10):e0141033. https:\/\/doi.org\/10.1371\/journal.pone.0141033","journal-title":"PLoS ONE"},{"issue":"6","key":"375_CR25","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","volume":"17","author":"RE Huebner","year":"1993","unstructured":"Huebner RE, Schein MF, Bass JB Jr (1993) The tuberculin skin test. Clin Infect Dis 17(6):968\u2013975. https:\/\/doi.org\/10.1093\/clinids\/17.6.968","journal-title":"Clin Infect Dis"},{"issue":"1","key":"375_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41598-020-58459-9","volume":"10","author":"M Yamasue","year":"2020","unstructured":"Yamasue M, Komiya K, Usagawa Y et al (2020) Factors associated with false negative interferon-\u03b3 release assay results in patients with tuberculosis: A systematic review with meta-analysis. Sci Rep 10(1):1607. https:\/\/doi.org\/10.1038\/s41598-020-58459-9","journal-title":"Sci Rep"},{"issue":"6","key":"375_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jinf.2009.09.012","volume":"59","author":"CH Liao","year":"2009","unstructured":"Liao CH, Lai CC, Tan CK et al (2009) False-negative results by enzyme-linked immunospot assay for interferon-gamma among patients with culture-confirmed tuberculosis. J Infect 59(6):421\u2013423. https:\/\/doi.org\/10.1016\/j.jinf.2009.09.012","journal-title":"J Infect"},{"issue":"12","key":"375_CR28","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1128\/CVI.05299-11","volume":"18","author":"D Vassilopoulos","year":"2011","unstructured":"Vassilopoulos D, Tsikrika S, Hatzara C et al (2011) Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 18(12):2102\u20132108. https:\/\/doi.org\/10.1128\/CVI.05299-11","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"375_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","volume":"161","author":"E Laffitte","year":"2009","unstructured":"Laffitte E, Janssens JP, Roux-Lombard P et al (2009) Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin test. Br J Dermatol. 161(4):797\u2013800. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09331.x","journal-title":"Br J Dermatol."},{"issue":"4","key":"375_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K L\u00f6nnroth","year":"2015","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I et al (2015) Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 45(4):928\u2013952. https:\/\/doi.org\/10.1183\/09031936.00214014","journal-title":"Eur Respir J"},{"key":"375_CR31","unstructured":"Field MJ (2001) Tuberculosis in the Workplace. The Occupational Tuberculosis Risk of Health Care Workers. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK222462\/"},{"issue":"6","key":"375_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/ajg.2009.162","volume":"104","author":"A Papa","year":"2009","unstructured":"Papa A, Mocci G, Bonizzi M et al (2009) Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol 104(6):1575\u20131586. https:\/\/doi.org\/10.1038\/ajg.2009.162","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"375_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/ajg.2011.211","volume":"106","author":"G Van Assche","year":"2011","unstructured":"Van Assche G, Lewis JD, Lichtenstein GR et al (2011) The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: safety. Am J Gastroenterol 106(9):1594\u20131603. https:\/\/doi.org\/10.1038\/ajg.2011.211","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"375_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1574886316666211109092354","volume":"17","author":"S Athimni","year":"2022","unstructured":"Athimni S, Slouma M, Dhahri R et al (2022) Tuberculosis Infection Under Anti-TNF Alpha Treatment. Curr Drug Saf 17(3):235\u2013240. https:\/\/doi.org\/10.2174\/1574886316666211109092354","journal-title":"Curr Drug Saf"},{"issue":"1","key":"375_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.semarthrit.2017.01.004","volume":"47","author":"SK Cho","year":"2017","unstructured":"Cho SK, Kim D, Won S et al (2017) Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum 47(1):102\u2013107. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.004","journal-title":"Semin Arthritis Rheum"},{"key":"375_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3899\/jrheum.140106","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Prignano F, Goletti D (2014) Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl 91:78\u201382. https:\/\/doi.org\/10.3899\/jrheum.140106","journal-title":"J Rheumatol Suppl"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T20:01:41Z","timestamp":1701201701000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00375-w","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Helsinki principles. Ethical approval was granted by the Medical Research Ethics Committee of Tokyo Medical University Hospital. The patient signed an informed consent form for publication of his clinical data, before the report is submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}